D.L. Feldman
Novartis Institute for Biomedical Research
LSB 2195
Novartis Pharmaceuticals Corp.
556 Morris Ave.
USA
Name/email consistency: high
- CGP 43371 paradoxically inhibits development of rabbit atherosclerotic lesions while inducing extra-arterial foam cell formation. Feldman, D.L., Sawyer, W.K., Jeune, M.R., Mogelesky, T.C., Von Linden-Reed, J., Forney Prescott, M. Atherosclerosis (2001)
- Enhanced expression of renal endothelin-converting enzyme-1 and endothelin-A-receptor mRNA in rats with interstitial fibrosis following ureter ligation. Feldman, D.L., Mogelesky, T.C., Chou, M., Jeng, A.Y. J. Cardiovasc. Pharmacol. (2000)
- Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor. Feldman, D.L., Mogelesky, T.C., Chou, M., Jeng, A.Y. J. Cardiovasc. Pharmacol. (2000)
- The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881. Feldman, D.L., Mogelesky, T.C., Sharif, R., Sawyer, W.K., Jeune, M., Hu, C.W., Leonards, K.S., Prescott, M.F. Atherosclerosis (1999)